Neola Medical

Neola Medical Quick Ratio

The Quick Ratio (Acid Test) of Neola Medical (NEOLA.ST) as of Oct 21, 2026 is 5.38. In the previous year, Quick Ratio (Acid Test) was 3.98 — a change of 35.20% (higher).

Quick Ratio

5.38

YoY

35.20%

Last updated:

Quick Ratio (Acid Test) of Neola Medical is 2025 5.38 . Quick Ratio (Acid Test) of Neola Medical was 2024 3.98 . It decreases by 35.20% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neola Medical Stock analysis

What does Neola Medical do? Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care. Neola Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neola Medical stock

Quick Ratio (Acid Test) of Neola Medical is 5.38 in 2025.

Quick Ratio (Acid Test) of Neola Medical changed from 3.98 to 5.38, representing a 35.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Neola Medical since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Neola Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neola Medical

All Key Metrics — Neola Medical